General Information
AstraZeneca DM2 D1683C00005
A Multi-Center, Randomised, Double-Blind, Active-Controlled, parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mt or Dapagliflozin 5mg all given as Add-on therapy to Metformin in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Alone.
| Protocol | D1683C00005 |
|---|---|
| Identifier | Site No: 7809 Study Code No: 8314897 |
| UID | f93c8c2f-b530-4689-8ebc-b9e19dbee98a |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2016-07-25 13:37 |
| Last Updated | 2016-07-25 13:37 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2016-09-30 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2016-09-12 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2017-09-18 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | AstraZeneca Pharmaceuticals |
|---|---|
| Division | AstraZeneca Pharamecuticals |
| Team | AstraZeneca Pharamecuticals LP |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Covance -LabCorp Drug Development |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
